Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral infections complicating primary immunodeficiencies.

P G Riches1

  • 1Department of Immunology, Charing Cross and Westminster Medical School, London.

La Clinica Terapeutica
|February 1, 1992
PubMed
Summary

Primary immunodeficiency (PI) compromises immune function, increasing susceptibility to viral infections, especially with T or B cell defects. This review categorizes PI by WHO classification, focusing on viral complications in antibody deficiencies and combined immunodeficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory cytokine (interleukin 6 and tumour necrosis factor alpha) release in a human whole blood system in response to Streptococcus pneumoniae serotype 14 and its capsular polysaccharide.

Clinical and experimental immunology·2002
Same author

Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay.

Annals of clinical biochemistry·2002
Same author

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2000
Same author

Imaging and laboratory investigation in herpes simplex encephalitis.

Journal of neurology, neurosurgery, and psychiatry·1999
Same author

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma.

Human gene therapy·1999
Same author

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

British journal of cancer·1998

Area of Science:

  • Immunology
  • Infectious Diseases
  • Genetics

Background:

  • Primary immunodeficiency (PI) encompasses diverse disorders stemming from immune system developmental or functional failures.
  • Viral infections are a significant concern in specific PIs, unlike complement or phagocyte deficiencies.
  • The presentation and pattern of viral diseases can be atypical in individuals with PI.

Purpose of the Study:

  • To review primary immunodeficiency states based on the World Health Organization (WHO) classification.
  • To analyze the role of viral infections as a major complication in various primary immunodeficiency categories.
  • To provide a detailed examination of viral infections in antibody deficiencies, combined immunodeficiency, and other major defect-associated immunodeficiencies.

Main Methods:

Related Experiment Videos

  • Literature review and synthesis of existing data on primary immunodeficiency and viral infections.
  • Classification of primary immunodeficiencies according to the established WHO criteria.
  • Analysis of the relationship between specific immune effector systems and susceptibility to viral pathogens.

Main Results:

  • Viral infections are frequently observed in T or B cell deficiencies, often presenting with unusual characteristics.
  • Complement or phagocyte deficiencies are less commonly associated with severe viral infections.
  • Antibody deficiencies, combined immunodeficiency, and immunodeficiencies with other major defects are highlighted for their significant infectious complications due to viruses.

Conclusions:

  • Primary immunodeficiencies necessitate careful consideration of viral infection risks, particularly those affecting T and B cells.
  • Understanding the WHO classification aids in predicting and managing viral complications in different PI states.
  • Targeted management strategies are crucial for mitigating severe outcomes from viral infections in susceptible primary immunodeficiency populations.